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Co-inhibitory immune checkpoint receptors have
become important targets for cancer immunotherapy.
Programmed death 1 (PD-1) has been well-characterized
on T cells in many cancer types, including head and
neck cancer (HNC), for its ability to mediate activation
and eventually T cell exhaustion in the tumor microen-
vironment. However, PD-1 expression on NK cells,
which are crucial innate immune effector cells against
cancer, remains largely undefined. In the setting of
HNC, NK cells mediate lysis of EGFR-overexpressing
tumor targets via cetuximab-mediated antibody depen-
dent cytotoxicity (ADCC). Indeed, cetuximab has shown
to be clinically effective but only to a modest extent.
Therefore, it is necessary to investigate how cetuximab
modulates activation of immune effector cell infiltrates
in the tumor microenvironment in order to improve or
extend its therapeutic efficacy. We hypothesized that
expression of PD-1 per se on NK cells may constitute a
marker of a chronically activated phenotype, which is
suppressed only after ligation by its cognate ligand pro-
grammed death ligand-1 (PD-L1). Thus, tumor cell-
expressing PD-L1 may present as a crucial mediator of
immunosuppression in the tumor microenvironment
decreasing cytotoxicity of cetuximab activated PD-1
expressing NK cells. Herein, using The Cancer Genome
Atlas (TCGA) data for 500 HNC patients’ tumors, we
found that PD-1 expression correlates with NK activa-
tion markers. Indeed, HNC patients also exhibit higher
levels of circulating and tumor infiltrating PD-1+ NK
cells, and neoadjuvant cetuximab treatment increased
this frequency in vitro and in vivo in a prospective
Phase II trial. In addition, anti-PD-1 mAb nivolumab
enhanced cetuximab mediated NK cell activation and
HNC cell lysis. Therefore, blocking PD-L1/PD-1 axis
may be a useful approach to reverse immune evasion of
HNC tumors to cetuximab therapy by reversing NK cell
dysfunction.
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